Provinces need to open up retail pot to private enterprise, Emerald Health CEO says

Emerald Health CEO Chris Wagner

 

You wouldn’t know it by the frigid temperatures, but summer in Canada is just around the corner, and with only a few months to go before the federal government makes good on its promise to legalize recreational marijuana, there’s still a lot of work to do. Which is why provinces like Ontario who plan to run their own pot outlets need to give private retail a second thought. That’s the opinion of Chris Wagner, CEO of Vancouver-based Emerald Health (TSXV:EMH), who says that he’s happier with the approach on offer in BC and Alberta where province-run distribution is charted to operate alongside private retail.

“That’s going to take some of the burden off the provincial government to get things up and running,” says Wagner, in conversation with Cantech Letter at the 5th Annual Cantech Investment Conference in Toronto. “As we all know, entrepreneurs can move very, very quickly.”

“Without that, what’ll happen is you’re going to have a population that’s not satisfied and they’ll point fingers and be upset,” says Wagner. “And it really won’t achieve the goals that Canada has, such as ensuring the health and safety of Canadians and moving it from the black market into a regulated market.”

Gunning to be a big-time contender in Canada’s burgeoning marijuana scene, Emerald has retrofitted a massive (1.1 million sq. feet) greenhouse on the outskirts of Vancouver into a cannabis growing facility, which when fully operational will produce 75,000 kg of pot a year.

“It’s extremely low cost,” says Wagner. “The company we’re partnering with, Village Farms, has been growing vegetables at the site for decades, in a very low margin, at-scale environment. We believe we’ll be able to grow for less than a dollar a gram, so there’s plenty of room to be extremely competitive.”

In fact, the company has an option for a lot more greenhouse space, enough to push production close to 300,000 kg, roughly half of the projected Canadian market. Asked whether he worries about finding a buyer for all that weed, especially as provincial boards are likely to hold all the power in deciding which producers will see their cannabis hit the shelves, Wagner appears unconcerned.

“There’s going to be more demand than supply, so if they want to service their customers, if they want people to transfer away from the black market and if they want to achieve what the federal government has set out for them to achieve, then they need to buy from people like us,” Wagner says.

“At Emerald, we’re pharmaceutical people and so we’ve approached growing cannabis with that kind of rigour,” he says. “The provinces can be comfortable buying from us because they know they’re purchasing something that’s been produced with good manufacturing practices, adhering to all the Health Canada regulations. We’ve done that our whole careers, producing at that level.”

Above and beyond the domestic front, though, Wagner thinks that Canada is uniquely positioned within a burgeoning global marijuana market. “Canadian companies are so far ahead of companies around the world in this space that this could truly be a long-term industry for Canada, selling intellectual property-protected products outside of the country,” says Wagner. “We will have a living laboratory in a couple of months and we’ll be able to export that.”

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: emh
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Is Magellan Aerospace stock a buy?

Its first quarter results are in the books and Paradigm Capital analyst J Marvin Wolff thinks there is money to… [Read More]

12 hours ago

Phunware is undervalued, Roth says

Ahead of the company's first quarter results, Roth MKM analyst Darren Aftahi thinks there is money to be made on… [Read More]

13 hours ago

Héroux-Devtek is a buy, Desjardins says

Ahead of the company's quarterly results, Desjardins Securities analyst Benoit Poirier likes what he sees from Héroux-Devtek (Héroux-Devtek Stock Quote,… [Read More]

14 hours ago

JUSH stock is a buy, Beacon says

With its first quarter results on deck, Beacon Securities analyst Russell Stanley thinks Jushi Holdings (Jushi Holdings Stock Quote, Chart,… [Read More]

1 day ago

Is Curaleaf stock still a buy?

The stock has been a steady climber since last October, but ahead of earnings is Curaleaf (Curaleaf Stock Quote, Chart,… [Read More]

1 day ago

OpenText price target cut at National Bank

Following third quarter results he describes as "in-line", National Bank Financial analyst Richard Tse has cut his price target on… [Read More]

2 days ago